The collaboration will see Antibody Analytics’ surface plasmon resonance (SPR) services offered on Science Exchange, an online marketplace for research services.
Guru Singh, director of scientific content at Science Exchange told us that SPR is a well-established bioanalytical tool used to analyze aspects of molecule binding and interactions.
“Antibody Analytics can design and develop bespoke bioassays as well as offer routine analysis on their already established assay platforms,” said Singh.
“We’ve been offering a lot of other services on their platform. So for us when we brought SPR on board it was kind of the obvious choice. There are other platforms as well, we do use them, but they’re not as effective for us as Science Exchange,” said Jamie Hodgson, director of strategic partnerships for Antibody Analytics, a UK-based contract research organization (CRO).
Bringing SPR on board through Antibody Analytics was an easy and important decision for both companies, said Singh. “Quick access to Antibody Analytics’ bioanalytical services can help researchers better understand the most complex of molecules, allowing them to accurately determine the characteristics and effects of the drugs,” he explained.
Hodgson told us that working with Science Exchange allows Antibody Analytics to easily engage with developers. As a CRO, he said it made sense to align themselves with where their customers’ attention is.
“For us, Science Exchange is a great platform because of the amount of access it has to drug developers and researchers and not just large pharma but all the way down to academic institutes. So, with their presence there it allows greater access to those people,” said Hodgson.
Hodgson furthered that companies like Science Exchange have provided a lot for CROs, and Antibody Analytics as a whole, because the platform allows companies better visibility. He stated, “Its simplification of how companies can work with each other. It translates to clearer messages and faster development. Everyone seems to be on the same page a lot quicker. I can foresee a lot of collaborations like this for CROs.”